Patents by Inventor Eveline Schaadt
Eveline Schaadt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167174Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.Type: ApplicationFiled: September 23, 2022Publication date: June 1, 2023Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
-
Patent number: 11492402Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.Type: GrantFiled: October 14, 2019Date of Patent: November 8, 2022Assignee: NOVARTIS AGInventors: Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
-
Publication number: 20220298251Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: October 29, 2021Publication date: September 22, 2022Inventors: Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
-
Patent number: 11180546Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.Type: GrantFiled: February 17, 2017Date of Patent: November 23, 2021Assignee: NOVARTIS AGInventors: Chikwendu Ibebunjo, Carsten Jacobi, Angelika Meyer, Eveline Schaadt, Anne-Ulrike Trendelenburg, Olga Vladimirovna Mitina
-
Publication number: 20210269540Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: ApplicationFiled: December 18, 2020Publication date: September 2, 2021Inventors: Marta COSENZA, Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
-
Patent number: 10899841Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: GrantFiled: March 6, 2019Date of Patent: January 26, 2021Assignee: NOVARTIS AGInventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20200140545Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.Type: ApplicationFiled: October 14, 2019Publication date: May 7, 2020Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
-
Publication number: 20190194341Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: ApplicationFiled: March 6, 2019Publication date: June 27, 2019Inventors: Marta COSENZA, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximillan Woisetschlaeger
-
Publication number: 20190135931Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: November 8, 2018Publication date: May 9, 2019Inventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20180179290Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.Type: ApplicationFiled: February 13, 2018Publication date: June 28, 2018Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20160368999Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20160347851Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: June 3, 2016Publication date: December 1, 2016Applicant: Novartis AGInventors: Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
-
Patent number: 9458240Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: GrantFiled: December 8, 2011Date of Patent: October 4, 2016Assignee: Novartis Pharma AGInventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Patent number: 9382326Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: GrantFiled: December 15, 2011Date of Patent: July 5, 2016Assignee: Novartis AGInventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Patent number: 9340620Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: GrantFiled: December 15, 2011Date of Patent: May 17, 2016Assignee: Novartis AGInventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20140186373Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: ApplicationFiled: December 8, 2011Publication date: July 3, 2014Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20120195913Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: December 15, 2011Publication date: August 2, 2012Inventors: Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
-
Publication number: 20120183529Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Inventors: Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
-
Patent number: 8106163Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: GrantFiled: July 15, 2009Date of Patent: January 31, 2012Assignee: Novartis AGInventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20100021452Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.Type: ApplicationFiled: July 15, 2009Publication date: January 28, 2010Inventors: Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger